0 Self-administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis from the RAPID StudyNovember 7, 2022PublicationBy Sub-editor0 Comments
0 In the NODE-302 trial, the commonly recorded adverse events were nasal discomfort, nasal congestion, rhinorrhea, epistaxis, sneezing, cough, throat irritation, headache, and increased lacrimation. These adverse events were local and transient.October 3, 2022PublicationBy Sub-editor0 Comments
0 Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardiaSeptember 20, 2022PublicationBy Sub-editor0 Comments
0 Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 StudyMay 4, 2022PublicationBy Sub-editor0 Comments
0 Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Intranasal Etripamil, a Short-Acting Calcium Channel Blocker, in Healthy Japanese and non-Japanese AdultsApril 4, 2022PublicationBy Sub-editor0 Comments
.png){kind=small}